MRNA Jul 2024 90.000 put

OPR - OPR Delayed price. Currency in USD
8.90
0.00 (0.00%)
As of 11:08AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close8.90
Open8.90
Bid8.20
Ask8.55
Strike90.00
Expiry date2024-07-19
Day's range8.90 - 8.90
Contract rangeN/A
Volume14
Open interest290
  • Simply Wall St.

    Recent uptick might appease Moderna, Inc. (NASDAQ:MRNA) institutional owners after losing 4.8% over the past year

    Key Insights Institutions' substantial holdings in Moderna implies that they have significant influence over the...

  • Motley Fool

    Better Healthcare AI Stock: Moderna vs. Doximity

    The AI in healthcare market is expected to top $100 billion by the end of the decade, and some companies are already leveraging this technology to advance their work. Two great examples are Moderna (NASDAQ: MRNA) and Doximity (NYSE: DOCS). Moderna isn't a novice when it comes to AI.

  • Motley Fool

    COVID Concerns Are Rising in China Again: Will This Send Moderna's Stock Soaring?

    The number of people with COVID-19 has been rising rapidly in China in recent weeks, and there are concerns that the government in Beijing could consider reviving its strict lockdown policies again. COVID-19 cases have been surging in China, largely due to the spread of the omicron XBB variants. In February, the Centers for Disease Control and Prevention pointed to early study results showing that for the  bivalent vaccine boosters created to target omicron variants, "[vaccine effectiveness] was generally similar against BA.5-related infections [original omicron] and XBB/XBB.1.5-related infections."

  • Motley Fool

    2 Healthcare AI Stocks to Buy on the Dip

    Artificial intelligence (AI) could change the way we treat and prevent illnesses, which makes it a highly valuable opportunity for companies. In fact, the global AI healthcare market is set to reach more than $100 billion later this decade, a Markets and Markets report shows. Two perfect examples are biotech Moderna (NASDAQ: MRNA) and medical device giant Medtronic (NYSE: MDT).

  • Simply Wall St.

    Moderna, Inc. (NASDAQ:MRNA) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

    With its stock down 8.4% over the past week, it is easy to disregard Moderna (NASDAQ:MRNA). However, a closer look at...

  • Motley Fool

    If You Invested $2,500 in Moderna in 2019, This Is How Much You Would Have Today

    You'd have a lot more money, but only if you resisted the temptation to take the initial profits.

  • Simply Wall St.

    Possible Bearish Signals With Moderna Insiders Disposing Stock \

    The fact that multiple Moderna, Inc. ( NASDAQ:MRNA ) insiders offloaded a considerable amount of shares over the past...

  • Yahoo Finance Video

    Moderna shares react to Covid resurgence news in China

    Yahoo Finance Live discusses a drop in shares of Moderna after a report of a resurgence of Covid in China.

  • Motley Fool

    Is Moderna Stock a Buy Now?

    Biotech giant Moderna (NASDAQ: MRNA) made a name for itself in the past couple of years as it developed and marketed one of the most successful coronavirus vaccines. Demand for coronavirus vaccines has started to fall, affecting Moderna's revenue. Is Moderna's stock worth considering, especially at current levels?

  • Zacks

    Is Trending Stock Moderna, Inc. (MRNA) a Buy Now?

    Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

  • Motley Fool

    3 Stocks You'll Be Glad You Bought at These Prices

    The good news is you really don't have to -- and you still can win in the stock market. The success of Moderna's (NASDAQ: MRNA) blockbuster coronavirus vaccine helped the stock soar earlier in the pandemic. Here's why they shouldn't: The vaccine represents just the beginning of Moderna's growth story.

  • Zacks

    Moderna (MRNA) Posts Upbeat Data on Protein Replacement Therapy

    Interim data from a study shows that Moderna's (MRNA) investigational therapy for propionic acidemia (PA) exhibited early signs of dose-dependent pharmacology and potential clinical benefits.

  • Motley Fool

    Biotech Stocks Are Already Risky -- Now There Are 3 New Headwinds to Face in 2023

    Biotech investors love to take on oodles of risk in hopes of getting an outsized reward when one of their bets finally pays off. While NHPs account for only 0.5% of the animal models used in biomedicine, biotechs and other researchers in the U.S. have faced a shortage of NHPs since at least 2019.

  • Motley Fool

    Here's How Moderna Turned a Profit in Q1 Despite Its Sales Declining by 69%

    Moderna (NASDAQ: MRNA) surprised investors last quarter when it didn't incur a loss despite a significant drop in sales. For the first three months of 2023, Moderna's revenue totaled just under $1.9 billion, which is just a fraction of the $6.1 billion it reported in the same period last year. Meanwhile, its operating expenses, totaling $2.2 billion, rose by more than 21%.

  • Motley Fool

    3 Magnificent Growth Stocks to Buy to Help Build a Millionaire Portfolio

    It's never too early to start building a portfolio that may eventually make you a millionaire. Today, many growth stocks are suffering, but in some cases, prospects over time remain bright. Amazon (NASDAQ: AMZN) was on an earnings roll, delivering gains in net income year after year -- until last year, when the company swung to a loss for the first time since 2014.

  • Motley Fool

    Ready to Buy the Dip? This Biotech Stock Is a Smart Buy

    Moderna (NASDAQ: MRNA) saw its shares jump in 2021 and 2022 on the back of strong sales of its COVID-19 vaccine Spikevax. Spikevax helped prove to the world the effectiveness of messenger RNA (mRNA) technology. The company advanced three COVID-19 vaccines from phase 1 to commercial status in a year.

  • Motley Fool

    Could Latecomer Moderna Match Big Pharma Rivals in RSV?

    Moderna (NASDAQ: MRNA) started its billion-dollar story with the coronavirus vaccine. The company plans to submit its candidate for use in older adults to regulators soon and aims for a 2024 launch. The U.S. Food and Drug Administration (FDA) recently approved GSK's vaccine -- the first RSV vaccine to ever win a nod.

  • Simply Wall St.

    An Intrinsic Calculation For Moderna, Inc. (NASDAQ:MRNA) Suggests It's 46% Undervalued

    Key Insights The projected fair value for Moderna is US$241 based on 2 Stage Free Cash Flow to Equity Moderna is...

  • Motley Fool

    Up 40% in 1 Day, Is Novavax Stock a Buy Now?

    On May 9, Novavax (NASDAQ: NVAX) shareholders got a much-needed reprieve from the stock's downward trajectory over the last year. Novavax's decline is a regrettable one. Its coronavirus vaccine candidate ran into regulatory issues during clinical development, and arrived on the market much later than those of competitors like Pfizer and Moderna.

  • Motley Fool

    Is It Too Late to Buy Moderna Stock?

    Demand for Moderna's (NASDAQ: MRNA) one and only product is on the decline. As we approach a post-pandemic situation, Moderna already has started to feel the impact. Does today's drop in vaccine sales mean it's too late to buy Moderna stock?

  • Motley Fool

    Novavax's New CEO Leads Vaccine Trial Success, and Big Layoffs Too

    Novavax (NASDAQ: NVAX) investors have been on edge ever since the company fell behind in the coronavirus vaccine race. To make matters worse, earlier this year, Novavax even questioned its ability to continue operations. Jacobs revealed details about his strategy to cut costs, manage cash flow, and match Novavax's size to the demand for its only product: the coronavirus vaccine.

  • Motley Fool

    3 Healthcare Stocks to Buy and Hold for the Next 10 Years

    It's always a great idea to buy stocks and hold them for the long term. That means at least five years. This offers you the opportunity to benefit from any dividend payments and/or growth in earnings.

  • Motley Fool

    The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer

    Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are two healthcare companies aiming to produce a vaccine for the respiratory syncytial virus (RSV). In trials, their vaccine candidates have been proving highly effective, and it may not be long before these COVID-19 vaccine makers are fighting for market share again -- this time in the RSV market. The Food and Drug Administration (FDA) recently approved an RSV vaccine, and it wasn't from either of these two companies.

  • Motley Fool

    Here's How Moderna Plans to Win in the Post-Emergency COVID Vaccine Market

    High demand for coronavirus vaccines earlier in the pandemic pushed Moderna's (NASDAQ: MRNA) earnings into the stratosphere. In fact, Moderna could continue to generate billions in revenues annually from its first -- and so far, only -- approved product. For example, Moderna sold its vaccine to the U.S. government for about $26 a dose.

  • Zacks

    Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know

    Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.